Identifying Novel Drug Treatment Options for Pediatric Osteosarcoma
Download Transcript, Episode 129 (84 KB)
Tomoo Iwakuma, MD, PhD
Length of Episode
Osteosarcoma is highly metastatic and drug-resistant cancer. The survival rate for metastatic osteosarcoma remains less than 20 percent for the last 40 years. Tomoo Iwakuma, MD, PhD, is leading research focused on the elucidation of mechanisms underlying osteosarcoma progression and the discovery of novel drugs against this osteosarcoma. His laboratory has identified a lead compound that specifically killed canine and human osteosarcoma cells lacking the activity of the tumor suppressor p53, with minimal impact on non-tumor cells. Join us as we visit with Dr. Iwakuma about this promising research.
Smith, Michael and Iwakuma, Tomoo, "Identifying Novel Drug Treatment Options for Pediatric Osteosarcoma" (2018). Transformational Pediatrics Podcast. 129.